Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Insilico Medicine (英矽智能) Signs Strategic Drug Discovery Partnership with Takeda (武田制药), Deal Worth Up to US$600 Million

Chinese AI drug discovery company Insilico Medicine (英矽智能) has signed a global strategic collaboration with Japanese pharmaceutical company Takeda (武田制药), with the total potential deal value reaching up to US$600 million. Announced in early July, the agreement marks another milestone in the international commercialization of China's AI-powered drug discovery technologies through collaboration with a leading multinational pharmaceutical company.

Drug Farm Raises $55 Million in First Closing of Series D Financing

According to EO (亿欧), Drug Farm (药物牧场) announced on July 13 that it had raised $55 million in the first closing of its Series D financing round.

EqualOcean Releases 2026 Chinese GoGlobal HealthTech Brands Top 10 at GGF2026

SHANGHAI, June 11, 2026 — EqualOcean officially released its 2026 Chinese GoGlobal HealthTech Brands Top 10 during the GoGlobal Forum of 100 2026 (GGF2026), one of China’s leading annual forums dedicated to globalization and international business expansion.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.